歐洲限制性勝胜肽藥物市場 – 分析與預測（2024-2040）

歐洲限制性勝胜肽藥物市場規模預計到2026年將達到6,000萬美元，到2040年將達到77.2億美元，2026-2040年預測期間複合年成長率為41.55%。

在創新的限制性胜肽管道的推動下，限制性胜肽藥物市場有望顯著成長，這些管道現在不僅僅針對受體。化學技術的進步、合成勝胜肽在治療方面的成功以及各種疾病的可負擔性也有助於預測期內的預期成長。

歐洲限制性勝胜肽藥物市場預計在未來幾年將顯著成長。這一市場擴張的主要驅動力之一是該地區強大的製藥業，其特點是研發、創新和強大的法規結構。歐洲製藥公司利用胜肽化學領域的最尖端科技和專業知識，一直處於開發限制性胜肽藥物的最前線。

此外，歐洲對新型治療方法的需求不斷成長，特別是在治療癌症、自體免疫疾病和代謝疾病等各種疾病方面。限制性胜肽因其特異性、提高功效和安全性的潛力而提供了一種有前景的解決方案。

此外，在歐洲，學術界、研究機構和製藥公司之間的合作正在加速限制性胜肽療法的發現和開發。這樣的協作生態系統促進創新，並將歐洲定位為限制性勝胜肽藥物市場的關鍵進入市場。

本報告考察了歐洲限制性勝胜肽藥物市場，提供了市場概述、按國家和公司分類的趨勢以及進入市場的公司概況。

目錄

執行摘要

第1章 定義

第2章 研究範圍

第3章調查方法

第4章市場概況

• 介紹
  • 限制性胜肽的結構和設計
  • 限制性胜肽的類型
• 抑制因素胜肽的進化
• 限制性胜肽藥物的開發
• 潛在的治療領域
• 價值鏈 - 主要相關人員
• 主要產業趨勢（按地區）
• 按行政途徑分類的主要行業趨勢
• 主要行業趨勢 - 技術進步
• 當前市場規模和成長潛力（十億美元），2024-2040 年
• COVID-19對限制性胜肽藥物市場的影響
  • 對限制性胜肽藥物公司的影響
  • 臨床試驗的暫停與恢復

第5章 歐洲

• 限制性勝胜肽藥物市場（按國家），十億美元，2024-2031
  • 歐洲

第6章 公司簡介

• Bicycle Therapeutics plc
• Spexis AG
• Santhera Pharmaceuticals
• Union Chimique Belge SA（UCB）
• Biosynth（Pepscan）

“The Europe Constrained Peptide Drugs Market Expected to Reach $7.72 Billion by 2040.”

Introduction to Europe constrained peptide drugs market

The market size is anticipated to be $0.06 billion in 2026 and is expected to reach $7.72 billion by 2040, growing at a CAGR of 41.55% during the forecast period 2026-2040. The constrained peptide drugs market is expected to experience significant growth, driven by innovative constrained peptide pipelines that now target more than just receptors. Advances in chemical technologies, the success of synthetic peptides in therapeutics, and their affordability across various diseases are also contributing to the projected growth in the forecast period.

Market Introduction

The Europe constrained peptide drugs market is poised for substantial growth in the coming years. One of the key drivers of this expansion is the region's robust pharmaceutical industry, characterized by a focus on research and development, innovation, and a strong regulatory framework. European pharmaceutical companies have been at the forefront of developing constrained peptide drugs, leveraging cutting-edge technologies and expertise in peptide chemistry.

Additionally, Europe has witnessed a growing demand for novel therapeutic approaches, particularly in the treatment of various diseases such as cancer, autoimmune disorders, and metabolic conditions. Constrained peptides offer a promising solution due to their specificity and potential for enhanced efficacy and safety profiles.

Furthermore, collaborative efforts between academia, research institutions, and pharmaceutical companies in Europe have accelerated the discovery and development of constrained peptide-based therapeutics. This collaborative ecosystem fosters innovation and positions Europe as a significant player in the constrained peptide drugs market.

Market Segmentation

Segmentation 1: by Country

• Germany
• U.K.
• France
• Italy
• Spain

Segmentation 2: by Company

• Bicycle Therapeutics plc
• Spexis AG
• Santhera Pharmaceuticals
• Union Chimique Belge S.A. (UCB)
• Biosynth (Pepscan)
• Zealand Pharma

How can this report add value to an organization?

Workflow/Innovation Strategy: Over the past decade, peptide drug discovery and development has witnessed a renaissance and scientific thrust as the industry has come to acknowledge the capability of peptide therapeutics in addressing unmet medical needs and the potential of this class of molecules to become a significant accompaniment or even favored alternative treatment to biologics and small molecules.

Peptide therapeutics have demonstrated a novel and selective yet safe mode of action for a wide range of indications. The existing and future development of constrained peptide drugs will continue to burgeon upon the strengths of constrained peptides and innovative technologies employed in the discovery and development, including peptide drug conjugates, multifunctional peptides, and cell-penetrating peptides. Furthermore, limitations associated with presently available peptides have resulted in an urgent need for new design, administration, and synthesis in peptide therapeutics, thereby leading to advancements in the development of constrained peptides.

Growth/Marketing Strategy: Constrained peptides provide noteworthy advantages over linear peptides. An increase in interest in constrained peptides due to their properties led to advancements in peptide synthesis technologies.

Competitive Strategy: Key players in the Europe constrained peptide drugs market have been analyzed and profiled in the study, including manufacturers involved in new product development, acquisitions, expansions, and strategic collaborations. Moreover, a detailed competitive benchmarking of the players operating in the Europe constrained peptide drugs market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.

Table of Contents

Executive Summary

1. Definition

• 1.1. Inclusion and Exclusion Criteria

2. Research Scope

• 2.1. Key Questions Answered in the Report

3. Research Methodology

• 3.1. Constrained Peptides: Research Methodology
• 3.2. Primary Data Sources
• 3.3. Secondary Data Sources
• 3.4. Market Estimation Model
• 3.5. Criteria for Company Profiling

4. Markets Overview

• 4.1. Introduction
  • 4.1.1. Structure and Design of Constrained Peptides
  • 4.1.2. Types of Constrained Peptides
• 4.2. Evolution of Constrained Peptides
• 4.3. Development of Constrained Peptides as Drugs
• 4.4. Potential Therapy Areas
• 4.5. Value Chain-Key Stakeholders
• 4.6. Key Industry Trends (by Region)
• 4.7. Key Industry Trends by Route of Administration
• 4.8. Key Industry Trends-Technological Advancements
• 4.9. Current Market Size and Growth Potential, $Billion, 2024-2040
• 4.1. COVID-19 Impact on Constrained Peptides Drugs Market
  • 4.10.1. Impact on Constrained Peptide Drugs Companies
  • 4.10.2. Clinical Trial Disruptions and Resumptions

5. Europe

• 5.1. Constrained Peptide Drugs Market (by Country), $Billion, 2024-2031
  • 5.1.1. Europe
    • 5.1.1.1. U.K.
    • 5.1.1.2. Germany
    • 5.1.1.3. France
    • 5.1.1.4. Italy
    • 5.1.1.5. Spain

6. Company Profiles

• 6.1. Overview
• 6.2. Bicycle Therapeutics plc
  • 6.2.1. Company Overview
  • 6.2.2. Role of Bicycle Therapeutics plc in the Constrained Peptide Drugs Market
  • 6.2.1. Current Status and Policies for Investigational Drugs
  • 6.2.2. Key Competitors of the Company
  • 6.2.3. Financials
  • 6.2.4. Key Insights about the Financial Health of the Company
  • 6.2.5. Corporate Strategies
    • 6.2.5.1. Synergistic Activities
    • 6.2.5.2. Funding
  • 6.2.6. Business Strategies
    • 6.2.6.1. Clinical Developments
    • 6.2.6.2. Regulatory and Legal
  • 6.2.7. Analyst Perspective
• 6.3. Spexis AG
  • 6.3.1. Company Overview
  • 6.3.2. Role of Spexis AG in the Constrained Peptide Drugs Market
  • 6.3.3. Current Status and Policies for Investigational Drugs
  • 6.3.4. Key Competitors of the Company
  • 6.3.5. Financials
  • 6.3.6. Key Insights about the Financial Health of the Company
  • 6.3.7. Corporate Strategies
    • 6.3.7.1. Funding
    • 6.3.7.2. Mergers and Acquisitions
    • 6.3.7.3. Synergistic activities
  • 6.3.8. Business Strategies
    • 6.3.8.1. Regulatory and Legal
  • 6.3.9. Analyst Perspective
• 6.4. Santhera Pharmaceuticals
  • 6.4.1. Company Overview
  • 6.4.2. Role of Santhera Pharmaceuticals in the Constrained Peptide Drugs Market
  • 6.4.3. Current Status and Policies for Investigational Drugs
  • 6.4.4. Key Competitors of the Company
  • 6.4.5. Financials
  • 6.4.6. Corporate Strategies
    • 6.4.6.1. Funding
  • 6.4.7. Business Strategies
    • 6.4.7.1. Clinical Developments
  • 6.4.8. Analyst Perspective
• 6.5. Union Chimique Belge S.A. (UCB)
  • 6.5.1. Company Overview
  • 6.5.2. Role of Union Chimique Belge S.A. (UCB) in the Constrained Peptide Drugs Market
  • 6.5.3. Current Status and Policies for Investigational Drugs
  • 6.5.4. Key Competitors of the Company
  • 6.5.5. Financials
  • 6.5.6. Key Insights about the Financial Health of the Company
  • 6.5.7. Corporate Strategies
    • 6.5.7.1. Mergers and Acquisitions
  • 6.5.8. Business Strategies
    • 6.5.8.1. Clinical Developments
    • 6.5.8.2. Regulatory and legal
  • 6.5.9. Analyst Perspective
• 6.6. Biosynth (Pepscan)
  • 6.6.1. Company Overview
  • 6.6.2. Role of Biosynth (Pepscan) in the Constrained Peptide Drugs Market
  • 6.6.3. Key Competitors of the Company
  • 6.6.4. Corporate Strategies
    • 6.6.4.1. License
  • 6.6.5. Business Strategies
    • 6.6.5.1. Product Launch
  • 6.6.6. Analyst Perspective
  • 6.6.7. Zealand Pharma
    • 6.6.7.1. ZP10000 (Preclinical)
      • 6.6.7.1.1. Product Profile

List of Figures

• Figure 1: Europe Total Number of Drugs Approved by the U.S. FDA, 2016-2021
• Figure 2: Europe Constrained Peptide Drugs Market, $Billion, 2024-2031
• Figure 3: Europe Constrained Peptide Drugs Market, $Billion, 2032-2040
• Figure 4: Europe Constrained Peptide Drugs: Impact Analysis
• Figure 5: Constrained Peptide Drugs Market (by Region), $Billion, 2024-2040
• Figure 6: Constrained Peptide Drugs Methodology
• Figure 7: Primary Research Methodology
• Figure 8: Epidemiology-Based Approach
• Figure 9: Inducing Conformational Effects
• Figure 10: Two Main Types of Constraints
• Figure 11: Methodology for Restricting Conformation in Peptides
• Figure 12: Types of Constrained Peptides
• Figure 13: Key Milestones in the Evolution of Constrained Peptides
• Figure 14: Major Factors Affecting Constrained Peptide Development
• Figure 15: Value Chain Analysis- Key Stakeholders
• Figure 16: Constrained Peptide Drugs Market (by Region), $Billion, 2024-2031
• Figure 17: Constrained Peptide Drugs Market (by Region), $Billion, 2032-2040
• Figure 18: Europe Constrained Peptide Drugs Market, $Billion, 2024-2031
• Figure 19: Europe Constrained Peptide Drugs Market, $Billion, 2032-2040
• Figure 20: Constrained Peptide Drugs Market (by Region)
• Figure 21: Constrained Peptide Drugs Market (by Region), $Billion, 2024-2040
• Figure 22: Europe Constrained Peptide Drugs Market, $Billion, 2024-2031
• Figure 23: Europe Constrained Peptide Drugs Market, $Billion, 2032-2040
• Figure 24: Europe: Market Dynamics
• Figure 25: Europe Constrained Peptide Drugs Market (by Country), $Billion, 2025 and 2040
• Figure 26: U.K. Constrained Peptide Drugs Market, $Billion, 2024-2031
• Figure 27: U.K. Constrained Peptide Drugs Market, $Billion, 2032-2040
• Figure 28: Germany Constrained Peptide Drugs Market, $Billion, 2024-2031
• Figure 29: Germany Constrained Peptide Drugs Market, $Billion, 2032-2040
• Figure 30: France Constrained Peptide Drugs Market, $Billion, 2024-2031
• Figure 31: France Constrained Peptide Drugs Market, $Billion, 2032-2040
• Figure 32: Italy Constrained Peptide Drugs Market, $Billion, 2024-2031
• Figure 33: Italy Constrained Peptide Drugs Market, $Billion, 2032-2040
• Figure 34: Spain Constrained Peptide Drugs Market, $Billion, 2024-2031
• Figure 35: Spain Constrained Peptide Drugs Market, $Billion, 2032-2040
• Figure 36: Total Number of Companies Profiled
• Figure 37: Bicycle Therapeutics plc: Product Portfolio
• Figure 38: Bicycle Therapeutics plc: Overall Financials, $Million, 2019-2021
• Figure 39: Bicycle Therapeutics plc: Revenue (by Region), $Million, 2019-2021
• Figure 40: Bicycle Therapeutics plc: R&D Expenditure, $Million, 2019-2021
• Figure 41: Spexis AG: Product Portfolio
• Figure 42: Spexis AG: Overall Financials, $Million, 2019-2021
• Figure 43: Spexis AG: R&D Expenditure, $Million, 2019-2021
• Figure 44: Santhera Pharmaceuticals: Product Portfolio
• Figure 45: Santhera Pharmaceuticals: Overall Financials, $Million, 2019-2021
• Figure 46: Union Chimique Belge S.A. (UCB): Product Portfolio
• Figure 47: Union Chimique Belge S.A. (UCB): Overall Financials, $Million, 2019-2021
• Figure 48: Union Chimique Belge S.A. (UCB): R&D Expenditure, $Million, 2019-2021
• Figure 49: Biosynth (Pepscan): Product Portfolio

List of Tables

• Table 1: Potential Indications of Constrained Peptide Drugs
• Table 2: Potential Therapy Areas of Constrained Peptide Drugs
• Table 3: Route of Administration of Constrained Peptide Drugs
• Table 4: Impact of COVID-19 on Constrained Peptide Drug Companies